Literature DB >> 21772034

Proteolysis of the class II-associated invariant chain generates a peptide binding site in intracellular HLA-DR molecules. Proc. Natl. Acad. Sci. USA. 1991. 88: 3150-3154.

Paul A Roche1, Peter Cresswell.   

Abstract

HLA-DR molecules are heterodimeric transmembrane glycoproteins that associate intracellularly with a polypeptide known as the invariant (I) chain. Shortly before expression of the HLA-DR αβ dimer on the cell surface, however the I chain is removed from the intracellular αβI complex by a mechanism thought to involve proteolysis . In this report, we show that treatment of purified αβI with the cysteine proteinase cathepsin B results in the specific proteolysis of the HLA-DR-associated I chain in vitro. As a consequence of this, the I chain is removed and free αβ dimers are released from αβI. Although αβI fails to bind an immunogenic peptide, the released αβ dimers acquire the ability to bind the peptide after proteolysis of the I chain. These results suggest that the I chain inhibits immunogenic peptide binding to αβI early during intracellular transport and demonstrate that proteolysis is likely to be the in vivo mechanism of I chain removal.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21772034

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  2 in total

1.  Dynamic Changes in the Intracellular Association of Selected Rab Small GTPases with MHC Class II and DM during Dendritic Cell Maturation.

Authors:  Gibrán Pérez-Montesinos; Orestes López-Ortega; Jessica Piedra-Reyes; Laura C Bonifaz; José Moreno
Journal:  Front Immunol       Date:  2017-03-27       Impact factor: 7.561

2.  HIV-1 envelope resistance to proteasomal cleavage: implications for vaccine induced immune responses.

Authors:  Nicholas J Steers; Silvia Ratto-Kim; Mark S de Souza; Jeffrey R Currier; Jerome H Kim; Nelson L Michael; Carl R Alving; Mangala Rao
Journal:  PLoS One       Date:  2012-08-06       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.